文献速递心力衰竭与心肌病

医院心力衰竭药物治疗评分与临床结局及费用的关联

Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs.
PubMed 文献 · JAMA Cardiol · 2024-01-01

结果显示医院GDMT评分存在显著差异,且较高评分与较低死亡率、较低死亡或心衰再住院、更多居家时间及较低费用相关。

要点

  • 医院出院GDMT评分存在显著差异(AMOR 1.23)。
  • 较高GDMT评分与较低死亡率和死亡或心衰再住院相关。
  • 较高GDMT评分与更多居家时间和较低费用相关。

核心结论

  • 医院间GDMT评分、临床结局和费用存在显著差异。
  • 出院时较高GDMT评分与较低死亡率、较低死亡或心衰再住院、更多居家时间和较低费用相关。

研究设计与样本

  • 回顾性队列研究,2015年1月至2019年9月,纳入Get With the Guidelines-Heart Failure注册中射血分数降低的心力衰竭住院患者。

主要发现

  • 出院GDMT评分医院间差异显著(AMOR 1.23;95% CI 1.21-1.26)。
  • 临床结局医院间差异显著:死亡率AMOR 1.17(95% CI 1.14-1.24),心衰再住院AMOR 1.22(95% CI 1.18-1.27),死亡或心衰再住院AMOR 1.21(95% CI 1.18-1.26),居家时间AMOR 1.07(95% CI 1.06-1.10)。
  • 费用医院间差异显著(AMOR 1.23;95% CI 1.21-1.26)。
  • 较高医院GDMT评分与较低医院死亡率相关(Spearman ρ -0.22;95% CI -0.32至-0.12;P < .001)。
  • 较高医院GDMT评分与较低死亡或心衰再住院相关(Spearman ρ -0.17;95% CI -0.26至-0.06;P = .002),与更多居家时间相关(Spearman ρ 0.14;95% CI 0.03-0.24;P = .01),与较低费用相关(Spearman ρ -0.11;95% CI -0.21至0;P = .047),但与心衰再住院无显著相关(Spearman ρ -0.10;95% CI -0.20至0;P = .06)。

临床怎么用

  • 提高医疗价值的工作应包括优化GDMT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A composite score for guideline-directed medical therapy (GDMT) for patients with heart failure (HF) is associated with increased survival. Whether hospital performance according to a GDMT score is associated with a broader array of clinical outcomes at lower costs is unknown. OBJECTIVES: To evaluate hospital variability in GDMT score at discharge, 90-day risk-standardized clinical outcomes and costs, and associations between hospital GDMT score and clinical outcomes and costs. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study conducted from January 2015 to September 2019. Included for analysis were patients hospitalized for HF with reduced ejection fraction (HFrEF) in the Get With the Guidelines-Heart Failure Registry, a national hospital-based quality improvement registry. Study data were analyzed from July 2022 to April 2023. EXPOSURES: GDMT score at discharge. MAIN OUTCOMES AND MEASURES: Hospital variability in GDMT score, a weighted index from 0 to 1 of GDMT prescribed divided by the number of medications eligible, at discharge was evaluated using a generalized linear mixed model using the hospital as a random effect and quantified with the adjusted median odds ratio (AMOR). Parallel analyses centering on 90-day mortality, HF rehospitalization, mortality or HF rehospitalization, home time, and costs were performed. Costs were assessed from the perspective of the Centers of Medicare & Medicaid Services. Associations between hospital GDMT score and clinical outcomes and costs were evaluated using Spearman coefficients. RESULTS: Among 41 161 patients (median [IQR] age, 78 [71-85] years; 25 546 male [62.1%]) across 360 hospitals, there was significant hospital variability in GDMT score at discharge (AMOR, 1.23; 95% CI, 1.21-1.26), clinical outcomes (mortality AMOR, 1.17; 95% CI, 1.14-1.24; HF rehospitalization AMOR, 1.22; 95% CI, 1.18-1.27; mortality or HF rehospitalization AMOR, 1.21; 95% CI, 1.18-1.26; home time AMOR, 1.07; 95% CI, 1.06-1.10) and costs (AMOR, 1.23; 95% CI, 1.21-1.26). Higher hospital GDMT score was associated with lower hospital mortality (Spearman ρ, -0.22; 95% CI, -0.32 to -0.12; P < .001), lower mortality or HF rehospitalization (Spearman ρ, -0.17; 95% CI, -0.26 to -0.06; P = .002), more home time (Spearman ρ, 0.14; 95% CI, 0.03-0.24; P = .01), and lower cost (Spearman ρ, -0.11; 95% CI, -0.21 to 0; P = .047) but not with HF rehospitalization (Spearman ρ, -0.10; 95% CI, -0.20 to 0; P = .06). CONCLUSIONS AND RELEVANCE: Results of this cohort study reveal that hospital variability in GDMT score, clinical outcomes, and costs was significant. Higher GDMT score at discharge was associated with lower mortality, lower mortality or hospitalization, more home time, and lower cost. Efforts to increase health care value should include GDMT optimization.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Polsinelli VB, Sun JL, Greene SJ, et al. Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs. JAMA Cardiol. 2024. PMID: 39320905. doi:10.1001/jamacardio.2024.2969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。